Ophthalmology Drug Development Pipeline Review, 2016


#877731

633pages

GBI Research

$ 3995

In Stock

Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, and particularly blindness, can arise. Although there are a number of treatments approved in ophthalmology, there are currently no curative therapies for any of these indications. In particular, there are strong unmet needs within age-related macular degeneration and glaucoma, which can lead to blindness if not adequately treated.

Although there is a high degree of failure and uncertainty within the R&D of pharmaceuticals, there is a great deal of interest in ophthalmology development. Overall, there are over 700 products in active development in the ophthalmology therapy area, making it one of the largest therapy area pipelines.

Although two thirds of products in development for ophthalmology disorders are at the Discovery or Preclinical stage of development, the number of drugs in the pipeline is very high, creating strong potential for a blockbuster drug to enter the market.

The report provides comprehensive information on the pipeline development landscape for glaucoma, age-related macular degeneration, diabetic retinopathy, diabetic macular edema and keratoconjunctivitis sicca (dry eye), from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

  • Which companies are the most active within the pipeline for ophthalmology?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have occurred in ophthalmology?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication.
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each.
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these.
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.

Table of Contents

1. Table of Contents
1.1. List of Tables
1.2. List of Figures

2. Introduction
2.1. Ophthalmology Therapeutics Report Coverage

3. Therapeutics Development by Stage
3.1. Age Related Macular Degeneration
3.2. Diabetic Retinopathy
3.3. Diabetic Macular Edema
3.4. Keratoconjunctivitis sicca (Dry Eye)
3.5. Glaucoma

4. Therapeutics under Development by Companies
4.1. Age Related Macular Degeneration
4.2. Diabetic Retinopathy
4.3. Diabetic Macular Edema
4.4. Keratoconjunctivitis sicca (Dry Eye)
4.5. Glaucoma

5. Therapeutics under Investigation by Universities/Institutes
5.1. Age Related Macular Degeneration
5.2. Diabetic Retinopathy
5.3. Diabetic Macular Edema
5.4. Keratoconjunctivitis sicca (Dry Eye)
5.5. Glaucoma

6. Pipeline Products Glance
6.1. Age Related Macular Degeneration
6.2. Diabetic Retinopathy
6.3. Diabetic Macular Edema
6.4. Keratoconjunctivitis sicca (Dry Eye)
6.5. Glaucoma

7. Products under Development by Companies
7.1. Age Related Macular Degeneration
7.2. Diabetic Retinopathy
7.3. Diabetic Macular Edema
7.4. Keratoconjunctivitis sicca (Dry Eye)
7.5. Glaucoma

8. Products under Investigation by Universities/Institutes
8.1. Age Related Macular Degeneration
8.2. Diabetic Retinopathy
8.3. Diabetic Macular Edema
8.4. Keratoconjunctivitis sicca (Dry Eye)
8.5. Glaucoma

9. Companies Involved in Therapeutics Development
9.1. Age Related Macular Degeneration
9.2. Diabetic Retinopathy
9.3. Diabetic Macular Edema
9.4. Keratoconjunctivitis sicca (Dry Eye)
9.5. Glaucoma

10. Therapeutics Assessment
10.1. Age Related Macular Degeneration
10.2. Diabetic Retinopathy
10.3. Diabetic Macular Edema
10.4. Keratoconjunctivitis sicca (Dry Eye)
10.5. Glaucoma

11. Recent Pipeline Updates
11.1. Age Related Macular Degeneration
11.2. Diabetic Retinopathy

12. Dormant Projects
12.1. Age Related Macular Degeneration
12.2. Diabetic Retinopathy
12.3. Diabetic Macular Edema
12.4. Keratoconjunctivitis sicca (Dry Eye)
12.5. Glaucoma

13. Discontinued Products
13.1. Age Related Macular Degeneration
13.2. Diabetic Retinopathy
13.3. Diabetic Macular Edema
13.4. Keratoconjunctivitis sicca (Dry Eye)
13.5. Glaucoma

14. Product Development Milestones
14.1. Age Related Macular Degeneration
14.2. Diabetic Retinopathy
14.3. Diabetic Macular Edema
14.4. Keratoconjunctivitis sicca (Dry Eye)
14.5. Glaucoma

15. Appendix
15.1. Research Methodology
15.2. Secondary Research
15.3. Contact Us
15.4. Disclaimer

Table 1: Number of Products under Development for Age Related Macular Degeneration
Table 2: Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis
Table 3: Number of Products under Development for Diabetic Retinopathy
Table 4: Number of Products under Development for Diabetic Retinopathy - Comparative Analysis
Table 5: Number of Products under Development for Diabetic Macular Edema
Table 6: Number of Products under Development for Diabetic Macular Edema - Comparative Analysis
Table 7: Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye)
Table 8: Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis
Table 9: Number of Products under Development for Glaucoma, H2 2016
Table 10: Number of Products under Development for Glaucoma - Comparative Analysis, H2 2016
Table 11: Number of Products under Development by Companies
Table 12: Number of Products under Development by Companies (Contd..1)
Table 13: Number of Products under Development by Companies (Contd..2)
Table 14: Number of Products under Development by Companies (Contd..3)
Table 15: Number of Products under Development by Companies (Contd..4)
Table 16: Number of Products under Development by Companies (Contd..5)
Table 17: Number of Products under Development by Companies (Contd..6)
Table 18: Number of Products under Development by Companies (Contd..7)
Table 19: Number of Products under Development by Companies (Contd..8)
Table 20: Number of Products under Development by Companies (Contd..9)
Table 21: Number of Products under Development by Companies
Table 22: Number of Products under Development by Companies (Contd..1)
Table 23: Number of Products under Development by Companies (Contd..2)
Table 24: Number of Products under Development by Companies
Table 25: Number of Products under Development by Companies (Contd..1)
Table 26: Number of Products under Development by Companies (Contd..2)
Table 27: Number of Products under Development by Companies
Table 28: Number of Products under Development by Companies (Contd..1)
Table 29: Number of Products under Development by Companies (Contd..2)
Table 30: Number of Products under Development by Companies, H2 2016
Table 31: Number of Products under Development by Companies, H2 2016 (Contd..1)
Table 32: Number of Products under Development by Companies, H2 2016 (Contd..2)
Table 33: Number of Products under Development by Companies, H2 2016 (Contd..3)
Table 34: Number of Products under Development by Companies, H2 2016 (Contd..4)
Table 35: Number of Products under Investigation by Universities/Institutes
Table 36: Number of Products under Investigation by Universities/Institutes
Table 37: Number of Products under Investigation by Universities/Institutes
Table 38: Number of Products under Investigation by Universities/Institutes
Table 39: Number of Products under Investigation by Universities/Institutes, H2 2016
Table 40: Comparative Analysis by Late Stage Development
Table 41: Comparative Analysis by Clinical Stage Development
Table 42: Comparative Analysis by Early Stage Development
Table 43: Comparative Analysis by Unknown Stage Development
Table 44: Comparative Analysis by Clinical Stage Development
Table 45: Comparative Analysis by Early Stage Development
Table 46: Comparative Analysis by Unknown Stage Development
Table 47: Comparative Analysis by Late Stage Development
Table 48: Comparative Analysis by Clinical Stage Development
Table 49: Comparative Analysis by Early Stage Development
Table 50: Comparative Analysis by Unknown Stage Development
Table 51: Comparative Analysis by Late Stage Development
Table 52: Comparative Analysis by Clinical Stage Development
Table 53: Comparative Analysis by Early Stage Development
Table 54: Comparative Analysis by Unknown Stage Development
Table 55: Comparative Analysis by Late Stage Development, H2 2016
Table 56: Comparative Analysis by Clinical Stage Development, H2 2016
Table 57: Comparative Analysis by Early Stage Development, H2 2016
Table 58: Comparative Analysis by Unknown Stage Development, H2 2016
Table 59: Products under Development by Companies
Table 60: Products under Development by Companies (Contd..1)
Table 61: Products under Development by Companies (Contd..2)
Table 62: Products under Development by Companies (Contd..3)
Table 63: Products under Development by Companies (Contd..4)
Table 64: Products under Development by Companies (Contd..5)
Table 65: Products under Development by Companies (Contd..6)
Table 66: Products under Development by Companies (Contd..7)
Table 67: Products under Development by Companies (Contd..8)
Table 68: Products under Development by Companies (Contd..9)
Table 69: Products under Development by Companies (Contd..10)
Table 70: Products under Development by Companies (Contd..11)
Table 71: Products under Development by Companies
Table 72: Products under Development by Companies (Contd..1)
Table 73: Products under Development by Companies (Contd..2)
Table 74: Products under Development by Companies (Contd..3)
Table 75: Products under Development by Companies
Table 76: Products under Development by Companies (Contd..1)
Table 77: Products under Development by Companies (Contd..2)
Table 78: Products under Development by Companies
Table 79: Products under Development by Companies (Contd..1)
Table 80: Products under Development by Companies (Contd..2)
Table 81: Products under Development by Companies (Contd..3)
Table 82: Products under Development by Companies, H2 2016
Table 83: Products under Development by Companies, H2 2016 (Contd..1)
Table 84: Products under Development by Companies, H2 2016 (Contd..2)
Table 85: Products under Development by Companies, H2 2016 (Contd..3)
Table 86: Products under Development by Companies, H2 2016 (Contd..4)
Table 87: Products under Development by Companies, H2 2016 (Contd..5)
Table 88: Products under Investigation by Universities/Institutes
Table 89: Products under Investigation by Universities/Institutes
Table 90: Products under Investigation by Universities/Institutes
Table 91: Products under Investigation by Universities/Institutes
Table 92: Products under Investigation by Universities/Institutes, H2 2016
Table 93: Age Related Macular Degeneration - Pipeline by AC Immune SA
Table 94: Age Related Macular Degeneration - Pipeline by Achillion Pharmaceuticals, Inc.
Table 95: Age Related Macular Degeneration - Pipeline by Aciont Inc.
Table 96: Age Related Macular Degeneration - Pipeline by AdAlta Pty Ltd.
Table 97: Age Related Macular Degeneration - Pipeline by Adverum Biotechnologies, Inc.
Table 98: Age Related Macular Degeneration - Pipeline by Aerie Pharmaceuticals, Inc.
Table 99: Age Related Macular Degeneration - Pipeline by Aerpio Therapeutics, Inc.
Table 100: Age Related Macular Degeneration - Pipeline by Alimera Sciences, Inc.
Table 101: Age Related Macular Degeneration - Pipeline by Alkeus Pharmaceuticals, Inc.
Table 102: Age Related Macular Degeneration - Pipeline by Allergan Plc
Table 103: Age Related Macular Degeneration - Pipeline by Allinky Biopharma
Table 104: Age Related Macular Degeneration - Pipeline by Alteogen Inc.
Table 105: Age Related Macular Degeneration - Pipeline by Amakem NV
Table 106: Age Related Macular Degeneration - Pipeline by Amarna Therapeutics B.V.
Table 107: Age Related Macular Degeneration - Pipeline by Ampio Pharmaceuticals, Inc.
Table 108: Age Related Macular Degeneration - Pipeline by Amyndas Pharmaceuticals LLC
Table 109: Age Related Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc.
Table 110: Age Related Macular Degeneration - Pipeline by Apexigen, Inc.
Table 111: Age Related Macular Degeneration - Pipeline by Applied Genetic Technologies Corporation
Table 112: Age Related Macular Degeneration - Pipeline by Astellas Pharma Inc.
Table 113: Age Related Macular Degeneration - Pipeline by Benitec Biopharma Limited
Table 114: Age Related Macular Degeneration - Pipeline by BIOCAD
Table 115: Age Related Macular Degeneration - Pipeline by Biokine Therapeutics Ltd.
Table 116: Age Related Macular Degeneration - Pipeline by BioMAS Ltd.
Table 117: Age Related Macular Degeneration - Pipeline by Biomics Biotechnologies Co., Ltd.
Table 118: Age Related Macular Degeneration - Pipeline by Biophytis SAS
Table 119: Age Related Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH
Table 120: Age Related Macular Degeneration - Pipeline by Caladrius Biosciences, Inc.
Table 121: Age Related Macular Degeneration - Pipeline by Catalyst Biosciences, Inc.
Table 122: Age Related Macular Degeneration - Pipeline by Cell Cure Neurosciences, Ltd.
Table 123: Age Related Macular Degeneration - Pipeline by Charlesson LLC.
Table 124: Age Related Macular Degeneration - Pipeline by Cipla Ltd.
Table 125: Age Related Macular Degeneration - Pipeline by Clanotech AB
Table 126: Age Related Macular Degeneration - Pipeline by Clearside BioMedical, Inc.
Table 127: Age Related Macular Degeneration - Pipeline by Clonz Biotech Private Limited
Table 128: Age Related Macular Degeneration - Pipeline by Coherus BioSciences, Inc.
Table 129: Age Related Macular Degeneration - Pipeline by Colby Pharmaceutical Company
Table 130: Age Related Macular Degeneration - Pipeline by Crinetics Pharmaceuticals, Inc.
Table 131: Age Related Macular Degeneration - Pipeline by Critical Pharmaceuticals Limited
Table 132: Age Related Macular Degeneration - Pipeline by Daiichi Sankyo Company, Limited
Table 133: Age Related Macular Degeneration - Pipeline by Delenex Therapeutics AG
Table 134: Age Related Macular Degeneration - Pipeline by Diffusion Pharmaceuticals Inc.
Table 135: Age Related Macular Degeneration - Pipeline by Digna Biotech, S.L.
Table 136: Age Related Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc.
Table 137: Age Related Macular Degeneration - Pipeline by Elsalys Biotech SAS
Table 138: Age Related Macular Degeneration - Pipeline by Exonate Limited
Table 139: Age Related Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd.
Table 140: Age Related Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd.
Table 141: Age Related Macular Degeneration - Pipeline by Formycon AG
Table 142: Age Related Macular Degeneration - Pipeline by Gene Techno Science Co., Ltd.
Table 143: Age Related Macular Degeneration - Pipeline by Genentech, Inc.
Table 144: Age Related Macular Degeneration - Pipeline by GenSight Biologics S.A.
Table 145: Age Related Macular Degeneration - Pipeline by GlaxoSmithKline Plc
Table 146: Age Related Macular Degeneration - Pipeline by Grupo Ferrer Internacional, S.A.
Table 147: Age Related Macular Degeneration - Pipeline by GTx, Inc.
Table 148: Age Related Macular Degeneration - Pipeline by HanAll Biopharma Co., Ltd.
Table 149: Age Related Macular Degeneration - Pipeline by Huabo Biopharm Co., Ltd.
Table 150: Age Related Macular Degeneration - Pipeline by iCo Therapeutics Inc.
Table 151: Age Related Macular Degeneration - Pipeline by Icon Bioscience, Inc.
Table 152: Age Related Macular Degeneration - Pipeline by Iconic Therapeutics, Inc.
Table 153: Age Related Macular Degeneration - Pipeline by Innovent Biologics, Inc.
Table 154: Age Related Macular Degeneration - Pipeline by Intellect Neurosciences, Inc.
Table 155: Age Related Macular Degeneration - Pipeline by International Stem Cell Corporation
Table 156: Age Related Macular Degeneration - Pipeline by Ionis Pharmaceuticals, Inc.
Table 157: Age Related Macular Degeneration - Pipeline by Jeil Pharmaceutical Co., Ltd.
Table 158: Age Related Macular Degeneration - Pipeline by Johnson & Johnson
Table 159: Age Related Macular Degeneration - Pipeline by Kadmon Corporation, LLC
Table 160: Age Related Macular Degeneration - Pipeline by Kala Pharmaceuticals, Inc.
Table 161: Age Related Macular Degeneration - Pipeline by Kodiak Sciences, Inc.
Table 162: Age Related Macular Degeneration - Pipeline by LeadArtis S.L.
Table 163: Age Related Macular Degeneration - Pipeline by M's Science Corporation
Table 164: Age Related Macular Degeneration - Pipeline by Mabion SA
Table 165: Age Related Macular Degeneration - Pipeline by MacuCLEAR, Inc.
Table 166: Age Related Macular Degeneration - Pipeline by Mitotech S.A.
Table 167: Age Related Macular Degeneration - Pipeline by Mitsubishi Tanabe Pharma Corporation
Table 168: Age Related Macular Degeneration - Pipeline by Navigen Pharmaceuticals, Inc.
Table 169: Age Related Macular Degeneration - Pipeline by Navya Biologicals Pvt Ltd
Table 170: Age Related Macular Degeneration - Pipeline by Neovacs SA
Table 171: Age Related Macular Degeneration - Pipeline by Neumedicines Inc.
Table 172: Age Related Macular Degeneration - Pipeline by Neuroptis Biotech
Table 173: Age Related Macular Degeneration - Pipeline by Neurotech Pharmaceuticals, Inc.
Table 174: Age Related Macular Degeneration - Pipeline by Novartis AG
Table 175: Age Related Macular Degeneration - Pipeline by Ocular Therapeutix, Inc.
Table 176: Age Related Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc.
Table 177: Age Related Macular Degeneration - Pipeline by Omeros Corporation
Table 178: Age Related Macular Degeneration - Pipeline by Ophthotech Corp.
Table 179: Age Related Macular Degeneration - Pipeline by Orphagen Pharmaceuticals, Inc.
Table 180: Age Related Macular Degeneration - Pipeline by Oxford BioMedica Plc
Table 181: Age Related Macular Degeneration - Pipeline by PanOptica, Inc.
Table 182: Age Related Macular Degeneration - Pipeline by Pfenex Inc.
Table 183: Age Related Macular Degeneration - Pipeline by Pfizer Inc.
Table 184: Age Related Macular Degeneration - Pipeline by Precision Ocular Ltd
Table 185: Age Related Macular Degeneration - Pipeline by Promedior, Inc.
Table 186: Age Related Macular Degeneration - Pipeline by pSivida Corp.
Table 187: Age Related Macular Degeneration - Pipeline by QLT Inc.
Table 188: Age Related Macular Degeneration - Pipeline by Quark Pharmaceuticals, Inc.
Table 189: Age Related Macular Degeneration - Pipeline by Ra Pharmaceuticals, Inc.
Table 190: Age Related Macular Degeneration - Pipeline by Regeneron Pharmaceuticals, Inc.
Table 191: Age Related Macular Degeneration - Pipeline by RegenxBio Inc.
Table 192: Age Related Macular Degeneration - Pipeline by Ribomic Inc.
Table 193: Age Related Macular Degeneration - Pipeline by RXi Pharmaceuticals Corporation
Table 194: Age Related Macular Degeneration - Pipeline by SanBio, Inc.
Table 195: Age Related Macular Degeneration - Pipeline by Santen Pharmaceutical Co., Ltd.
Table 196: Age Related Macular Degeneration - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd.
Table 197: Age Related Macular Degeneration - Pipeline by SciFluor Life Sciences, LLC
Table 198: Age Related Macular Degeneration - Pipeline by Sirnaomics, Inc.
Table 199: Age Related Macular Degeneration - Pipeline by Stealth BioTherapeutics Inc.
Table 200: Age Related Macular Degeneration - Pipeline by Sucampo Pharmaceuticals, Inc.
Table 201: Age Related Macular Degeneration - Pipeline by Sumitomo Dainippon Pharma Co., Ltd.
Table 202: Age Related Macular Degeneration - Pipeline by Sun Pharma Advanced Research Company Ltd.
Table 203: Age Related Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc.
Table 204: Age Related Macular Degeneration - Pipeline by TWi Pharmaceuticals, Inc.
Table 205: Age Related Macular Degeneration - Pipeline by Tyrogenex, Inc.
Table 206: Age Related Macular Degeneration - Pipeline by VasGene Therapeutics, Inc.
Table 207: Age Related Macular Degeneration - Pipeline by Wellstat Ophthalmics Corporation
Table 208: Age Related Macular Degeneration - Pipeline by Xbrane Biopharma AB
Table 209: Diabetic Retinopathy - Pipeline by Acucela Inc.
Table 210: Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals, Inc.
Table 211: Diabetic Retinopathy - Pipeline by Aerpio Therapeutics, Inc.
Table 212: Diabetic Retinopathy - Pipeline by Antisense Therapeutics Limited
Table 213: Diabetic Retinopathy - Pipeline by BCN Peptides, S.A.
Table 214: Diabetic Retinopathy - Pipeline by Biomar Microbial Technologies
Table 215: Diabetic Retinopathy - Pipeline by Charlesson LLC.
Table 216: Diabetic Retinopathy - Pipeline by Coherus BioSciences, Inc.
Table 217: Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals, Inc.
Table 218: Diabetic Retinopathy - Pipeline by Diffusion Pharmaceuticals Inc.
Table 219: Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd
Table 220: Diabetic Retinopathy - Pipeline by Dynamis Therapeutics, Inc.
Table 221: Diabetic Retinopathy - Pipeline by EyeGene, Inc.
Table 222: Diabetic Retinopathy - Pipeline by Foresee Pharmaceuticals, LLC

Figure 1: Number of Products under Development for Age Related Macular Degeneration
Figure 2: Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis
Figure 3: Number of Products under Development for Diabetic Retinopathy
Figure 4: Number of Products under Development for Diabetic Retinopathy - Comparative Analysis
Figure 5: Number of Products under Development for Diabetic Macular Edema
Figure 6: Number of Products under Development for Diabetic Macular Edema - Comparative Analysis
Figure 7: Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye)
Figure 8: Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis
Figure 9: Number of Products under Development for Glaucoma, H2 2016
Figure 10: Number of Products under Development for Glaucoma - Comparative Analysis, H2 2016
Figure 11: Number of Products under Development by Companies
Figure 12: Number of Products under Development by Companies
Figure 13: Number of Products under Development by Companies
Figure 14: Number of Products under Development by Companies
Figure 15: Number of Products under Development by Companies, H2 2016
Figure 16: Number of Products under Investigation by Universities/Institutes
Figure 17: Number of Products under Investigation by Universities/Institutes
Figure 18: Number of Products under Investigation by Universities/Institutes, H2 2016
Figure 19: Comparative Analysis by Late Stage Development
Figure 20: Comparative Analysis by Clinical Stage Development
Figure 21: Comparative Analysis by Early Stage Products
Figure 22: Comparative Analysis by Clinical Stage Development
Figure 23: Comparative Analysis by Early Stage Products
Figure 24: Comparative Analysis by Late Stage Development
Figure 25: Comparative Analysis by Clinical Stage Development
Figure 26: Comparative Analysis by Early Stage Products
Figure 27: Comparative Analysis by Late Stage Development
Figure 28: Comparative Analysis by Clinical Stage Development
Figure 29: Comparative Analysis by Early Stage Products
Figure 30: Comparative Analysis by Late Stage Development, H2 2016
Figure 31: Comparative Analysis by Clinical Stage Development, H2 2016
Figure 32: Comparative Analysis by Early Stage Products, H2 2016
Figure 33: Comparative Analysis by Unknown Stage Development, H2 2016
Figure 34: Assessment by Monotherapy Products
Figure 35: Number of Products by Top 10 Targets
Figure 36: Number of Products by Stage and Top 10 Targets
Figure 37: Number of Products by Top 10 Mechanism of Actions
Figure 38: Number of Products by Stage and Top 10 Mechanism of Actions
Figure 39: Number of Products by Top 10 Routes of Administration
Figure 40: Number of Products by Stage and Top 10 Routes of Administration
Figure 41: Number of Products by Top 10 Molecule Types
Figure 42: Number of Products by Stage and Top 10 Molecule Types
Figure 43: Assessment by Monotherapy Products
Figure 44: Number of Products by Top 10 Targets
Figure 45: Number of Products by Stage and Top 10 Targets
Figure 46: Number of Products by Top 10 Mechanism of Actions
Figure 47: Number of Products by Stage and Top 10 Mechanism of Actions
Figure 48: Number of Products by Top 10 Routes of Administration
Figure 49: Number of Products by Stage and Top 10 Routes of Administration
Figure 50: Number of Products by Top 10 Molecule Types
Figure 51: Number of Products by Stage and Top 10 Molecule Types
Figure 52: Assessment by Monotherapy Products
Figure 53: Number of Products by Top 10 Targets
Figure 54: Number of Products by Stage and Top 10 Targets
Figure 55: Number of Products by Top 10 Mechanism of Actions
Figure 56: Number of Products by Stage and Top 10 Mechanism of Actions
Figure 57: Number of Products by Routes of Administration
Figure 58: Number of Products by Stage and Routes of Administration
Figure 59: Number of Products by Molecule Types
Figure 60: Number of Products by Stage and Molecule Types
Figure 61: Assessment by Monotherapy Products
Figure 62: Number of Products by Top 10 Targets
Figure 63: Number of Products by Stage and Top 10 Targets
Figure 64: Number of Products by Top 10 Mechanism of Actions
Figure 65: Number of Products by Stage and Top 10 Mechanism of Actions
Figure 66: Number of Products by Top 10 Routes of Administration
Figure 67: Number of Products by Stage and Top 10 Routes of Administration
Figure 68: Number of Products by Molecule Types
Figure 69: Number of Products by Stage and Molecule Types
Figure 70: Assessment by Monotherapy Products, H2 2016
Figure 71: Assessment by Combination Products, H2 2016
Figure 72: Number of Products by Top 10 Targets, H2 2016
Figure 73: Number of Products by Stage and Top 10 Targets, H2 2016
Figure 74: Number of Products by Top 10 Mechanism of Actions, H2 2016
Figure 75: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Figure 76: Number of Products by Top 10 Routes of Administration, H2 2016
Figure 77: Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Figure 78: Number of Products by Top 10 Molecule Types, H2 2016
Figure 79: Number of Products by Stage and Top 10 Molecule Types, H2 2016